• Company
    • Overview
    • Leadership
    • Company History
    • CSR
    • Diversity
    • JSR LS
  • Newsroom
    • Latest News
    • Archives
    • In the News
    • Calendar
    • Press Kit
    • Media Inquiries
    • Xpressions Blog
  • Careers
    • Overview
    • Open Positions
    • GPTW
    • Submit Resume
  • Contact
    • General Inquiries
SELEXIS-logo-with-tagline-2016MAR19-V600-Full-Color
Selexis Logo Web
  • Capabilities
    • Overview
    • Cell Line Development
    • Clonality
  • Technologies
    • Overview
    • Gene Technology
    • CHO Cell Line
  • Solutions
    • Overview
    • Bispecifics
    • Difficult-to-Express Proteins
    • Gene to GMP
    • Monoclonal Antibodies
  • Pipeline
    • Overview
    • Partners
  • Knowledge Center
    • TECHNOLOGY FAQS
    • SCIENTIFIC PUBLICATIONS
    • SCIENTIFIC POSTERS
    • WHITE PAPERS AND ARTICLES
    • VIDEOS
    • FACT SHEETS
    • PRESENTATIONS
  • Company
    • Overview
    • Leadership
    • Company History
    • CSR
    • Diversity
    • JSR LS
  • Newsroom
    • Latest News
    • Archives
    • In the News
    • Calendar
    • Press Kit
    • Media Inquiries
    • Xpressions Blog
  • Careers
    • Overview
    • Open Positions
    • GPTW
    • Submit Resume
  • Contact
    • General Inquires

Capabilities

  • Overview
  • CLD
  • Clonality

Technologies

  • Overview
  • Gene Technology
  • CHO Cell Line

Solutions

  • Overview
  • Bispecifics
  • Difficult-to Express-Proteins
  • Gene to GMP

Pipeline

  • Overview
  • Testimonials
  • Partners

Knowledge Center

  • OVERVIEW
  • TECHNOLOGY FAQS
  • TECHNOLOGY SHEETS
  • SCIENTIFIC PUBLICATIONS
  • SCIENTIFIC POSTERS
  • WHITE PAPERS AND ARTICLES
  • VIDEOS
  • FACT SHEETS

Capabilities

  • Overview
  • CLD
  • Clonality

Technologies

  • Overview
  • Gene Technology
  • CHO Cell Line

Solutions

  • Overview
  • Bispecifics
  • Difficult-to Express-Proteins
  • Gene to GMP

Pipeline

  • Overview
  • Testimonials
  • Partners

Knowledge Center

Capabilities

  • Overview
  • CLD
  • Clonality

Technologies

  • Overview
  • Gene Technology
  • CHO Cell Line

Solutions

  • Overview
  • Bispecifics
  • Difficult-to Express-Proteins
  • Gene to GMP

Pipeline

  • Overview
  • Testimonials
  • Partners

Knowledge Center

Capabilities

  • Overview
  • CLD
  • Clonality

Technologies

  • Overview
  • Gene Technology
  • CHO Cell Line

Solutions

  • Overview
  • Bispecifics
  • Difficult-to Express-Proteins
  • Gene to GMP

Pipeline

  • Overview
  • Testimonials
  • Partners

Knowledge Center

Capabilities

  • Overview
  • CLD
  • Clonality

Technologies

  • Overview
  • Gene Technology
  • CHO Cell Line

Solutions

  • Overview
  • Bispecifics
  • Difficult-to Express-Proteins
  • Gene to GMP

Pipeline

  • Overview
  • Testimonials
  • Partners

Knowledge Center

  • Latest News
  • Archives
  • In the News
  • Calendar
  • Press Kit
  • Media Inquiries
  • Xpressions Blog
Selexis CHO Cells in Suspension-1

Press Kit

 

Corporate Logos


 

Selexis Logo Web
 
Selexis Logo (png)
SELEXIS logo with tagline 2016MAR19 V1200-Full Color
 
Selexis Logo with Tagline (png)
JSRLogo-gray
 
A JSR Life Sciences Company Logo (png)

Videos and Photos


 

Fact Sheets and Backgrounders


 

SELEXIS-Corporate-Overview-Thumbnail optimized-2019OCT25-V24-D
 
Corporate Overview 
SELEXIS-Rescue-Thumbnail-2019MAY22-V09-FD
 
Rescue Promising Programs
SELEXIS-SUREtechnology-Thumbnail-2019MAY22-V11-FD
 
SUREtechnology Platform™
SELEXIS-Research-Cell-Bank-Development-Thumbnail-2019OCT03-V17-FD
 
Research Cell Bank Development




Selexis CHO cells high expressing mAB bispecific antibody
 

Driven by Excellence. Guided by Science.


Connect with us.

From ubiquitous immunoglobulin-based drugs such as monoclonal and bi-specific antibodies and Fc Fusions to novel scaffolds and difficult-to-express proteins, Selexis is your partner of choice

 

 

Connect with Us

 

Explore the SUREtechnology Platform™


Selexis-Website-Test-Image-Container 1

Monoclonal Antibodies

For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving mAb therapeutics into the clinic and to the market.

Learn More
Selexis-Website-Test-Image-Container 2

Difficult-to-Express Proteins

At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.

Learn More
Selexis-Website-Test-Image-Container 3

Bispecific Antibodies

We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.

Learn More
  • Capabilities
  • Technologies
  • Solutions
  • Pipeline
  • Knowledge Center
  • Company
  • Newsroom
  • Careers
  • Contact
Selexis SA footer Logo

Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.

 

A JSR Life Sciences Company Logo
EN-BEST MEDIUM WORKPLACES_CMYK

Latest News

July 6, 2022

KBI Biopharma and Selexis Hold Joint Ribbon Cutting of the Expanded State-of-the-Art Facility in Geneva, Switzerland

Read More
May 11, 2022

Great Place to Work® Designates Selexis as a Best Workplace in Switzerland for Fifth Straight Year

Read More
  • Terms of Use
  • Privacy
  • Cookies
  • Social Media

Copyright© 2022 Selexis SA. All Rights Reserved.